ArticlePharmaceutics2022
A Brain-Targeted Approach to Ameliorate Memory Disorders in a Sporadic Alzheimer's Disease Mouse Model via Intranasal Luteolin-Loaded Nanobilosomes.
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 50 citations in OpenAlex.
- Disease mechanisms and translational barriers guide nanocarrier design for nose to brain delivery in Alzheimer's disease.Discover nano · 2026Review
- Signaling Pathways Triggering Therapeutical Potential of Marine-Derived Polysaccharides in Alzheimer's Disease: A Recent Review.Molecular neurobiology · 2026Review
- Luteolin and neuroinflammation: a multi-target therapeutic strategy for central nervous system disorders.Frontiers in pharmacology · 2026Review
- Luteolin as a dietary flavonoid for brain health: modulating neuroinflammation and cognitive decline in neurodegenerative disorders.Frontiers in nutrition · 2026Review
- Nanotechnology-enabled delivery of luteolin: a comprehensive review on multidisease therapeutic applications.Frontiers in pharmacology · 2026Review
- Advances in Bioactive Compounds from Plants and Their Applications in Alzheimer's Disease.Biomolecules · 2025Review
- Liposomal and Nanomaterial-Based Strategies for Targeted Alzheimer's Disease Therapy.ACS omega · 2025Review
- Innovative approach in Parkinson's targeting via berberine-loaded mucoadhesive surface-modified liposomes: a multi-faceted study.BMC pharmacology & toxicology · 2025Article
- Plant-based flavonoids and their nanoparticles: Latest arsenal against Alzheimer's disease.Drug delivery and translational research · 2025Review
- Exploring the hypoglycemic potential of HuGLP-1-loaded bilosomes in controlling type 2 diabetes mellitus.Therapeutic delivery · 2025Article
- Engineered nanoplatforms for brain-targeted co-delivery of phytochemicals in Alzheimer's disease: Rational design, blood-brain barrier penetration, and multi-target therapeutic synergy.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Review
- Dietary Polyphenols: Luteolin, Quercetin, and Apigenin as Potential Therapeutic Agents in the Treatment of Gliomas.Nutrients · 2025Review
- Intranasal Drug Delivery Technology in the Treatment of Central Nervous System Diseases: Challenges, Advances, and Future Research Directions.Pharmaceutics · 2025Review
- The Pharmaceutical and Pharmacological Potential Applications of Bilosomes as Nanocarriers for Drug Delivery.Molecules (Basel, Switzerland) · 2025Review
- Intranasal Mucoadhesive In Situ Gel of Glibenclamide-Loaded Bilosomes for Enhanced Therapeutic Drug Delivery to the Brain.Pharmaceutics · 2025Article
- Therapeutic Expedition of Luteolin against Brain-related Disorders: An Updated Review.Combinatorial chemistry & high throughput screening · 2025Review
- Nose-to-brain Drug Delivery System: An Emerging Approach to Chemotherapy-induced Cognitive Impairment.Pharmaceutical nanotechnology · 2025Review
- Recent Advancements in Lipid Nanoparticles-Based Phytoactives Delivery Systems for Neurodegenerative Diseases.International journal of nanomedicine · 2025Review
- Evaluation of Mucoadhesive Nano-Bilosomal In Situ Gels Containing Anti-Psychotic Clozapine for Treatment of Schizophrenia: In Vitro and In Vivo Studies.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Rutin loaded bilosomes for enhancing the oral activity and nephroprotective effects of rutin in potassium dichromate induced acute nephrotoxicity in rats.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Impaired memory and cognitive function are the main features of Alzheimer's disease (AD). Unfortunately, currently available treatments cannot cure or delay AD progression. Moreover, the blood-brain barrier hampers effective delivery of treatment to the brain. Therefore, we aimed to evaluate the impact of intranasally delivered luteolin on AD using bile-salt-based nano-vesicles (bilosomes). Different bilosomes were prepared using 2
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.